Fig. 5: In vivo pharmacokinetics and biodistribution of siRNA-Cy5@eS-BNVs. | Nature Communications

Fig. 5: In vivo pharmacokinetics and biodistribution of siRNA-Cy5@eS-BNVs.

From: Bioengineered nanovesicles for efficient siRNA delivery through ligand-receptor-mediated and enzyme-controlled membrane fusion

Fig. 5

a In vivo biodistribution of Cy5-labeled siRNA@eS-BNVs in A549ACE2+ tumor-bearing mice was measured by IVIS spectrum at 2, 12 and 24 h post i.v. injection. b Ex vivo imaging of Cy5-labeled siRNA@eS-BNVs distributed in tumors at 24 h post i.v. administration. c Quantification of Cy5-labeled siRNA@eS-BNVs in main organs and tumors at 24 h after i.v. injection of nanovesicles (n = 3 independent samples). d Extravasation of Cy5-labeled siRNA@eS-BNVs from blood vessels into tumor tissues at 24 h post i.v. injection. Scale bars, 50 μm. e Representative fluorescence images show the distribution of Cy5-labeled siRNA@eS-BNVs across the A549ACE2+ tumors at 24 h after i.v. administration. Green, A549ACE2+-EGFP tumors; red, siRNA-Cy5; white, blood vessel stained by anti-CD31 antibody. Scale bars, 100 μm. Avg, average. Experiments in (d and e) were repeated three times independently with similar results. Data in (c) is the mean ± s.d. p-values were determined by a two-way ANOVA test in (c). ****p < 0.0001. Source data are provided in a Source Data file.

Back to article page